Immunovative Inc. Announces the Appointment of Mr. Bruce Harmon as Chief Financial Officer, Effective Immediately

Immunovative Inc. Announces the Appointment of Mr. Bruce Harmon as Chief Financial Officer, Effective Immediately

9/21/2012 9:23:33 AM

NEW YORK, NY-- Immunovative, Inc. (OTCQB: IMUN) ("IMUN" or the "Company") announces today that it has appointed Mr. Bruce Harmon ("Mr. Harmon") as its Chief Financial Officer ("CFO") effective immediately.

Mr. Harmon, 54, has extensive experience building and managing the financial responsibilities of both publicly traded companies and innovative startups. For the past 25 years, Mr. Harmon has worked in senior financial positions, including CFO and/or director with various public companies listed on both the NASDAQ as well as more junior exchanges such as OTCBB. His many years of experience as a senior level executive, his vast knowledge of Sarbanes-Oxley regulations, and his superior rolodex will prove extremely valuable to the shareholders of the Company. Mr. Harmon's career experience spans numerous sectors, including but not limited to: pharmaceutical, construction, information technology, apparel, payment processing, and more and he currently serves in C-level roles and/or director with several publicly traded companies.

"Mr. Harmon brings important business and public company experience which will be advantageous to the Company as we progress in our business activities. In addition his rolodex will be highly valuable as the Company increases both its financing activities and its visibility to the investment community," stated Mr. Seth M. Shaw, Chairman and Chief Executive Officer of Immunovative, Inc.

Newly appointed CFO Mr. Harmon stated, "I am very pleased to join IMUN and assist the Company in its ultimate goal of advancing its promising technology with respect to treating late-stage cancer patients. I look forward to working closely with Mr. Shaw in creating significant and lasting shareholder value."

A Form 8K has already been filed in connection with this above-mentioned appointment.

About Immunovative, Inc.:
On December 12, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN's website at

About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL's website at:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.

For more information please contact:

Mr. Seth Shaw
Chairman & Chief Executive Officer
Immunovative, Inc.
New York: 917-796-9926
Montreal: 514-840-3697
Email: Email Contact

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.